TY - JOUR
T1 - Antibodies response induced by recombinant virus-like particles from Triatoma virus and chimeric antigens from Trypanosoma cruzi
AU - Maria Vasconcelos Queiroz, Aline
AU - Aleksandrovna Yanshina, Yulia
AU - Thays da Silva Rodrigues, Emily
AU - Luciano Neves Santos, Fred
AU - Alejandra Fiorani Celedon, Paola
AU - Maheshwari, Sweta
AU - Beatriz Gabelli, Sandra
AU - Stephanie Peucelle Rubio, Carla
AU - Durana, Aritz
AU - Guérin, Diego M.A.
AU - Sousa Silva, Marcelo
N1 - Funding Information:
This research was funded by Consejo Superior de Investigaciones Científicas (grant number COOPB20503 - CSIC, Spain) and Global Health and Tropical Medicine [grant number GHTM-UID/multi/04413/2013] and partially supported by grants to DMAG, from the Ministerio de Ciencia e Innovación [BFU2012-36241], Grupos Investigación UPV/EHU 2018 [GIU18/172], and Gobierno Vasco [Elkartek KK-2017/00008], Programa de empresas Innovadoras A1 2020 EKINZAILE, The Basque Country, Spain. This study also was supported by Coordenação de Aperfeiçaomento de Pessoal de Nível Superior (CAPES, Brazil).
Funding Information:
A.M.V.Q thanks the financial support provided by CAPES/Brazil through postgraduate. MSS thanks to CNPq/Brazil for the Research Grant (Bolsa de Produtividade). DMAG thanks a traveling grant to visit JHU from Fundaci?n Biof?sica Bizkaia (Spain). C.S.P.R. thanks a summer fellowship from the Basque Country government ?Becas Ikasiker de Colaboraci?n 2019?. We thank Dr. Yana Li (JHU) for technical assistance. TEM images were collected at the Servicio General de Microscop?a Anal?tica y de Alta Resoluci?n en Biomedicina (SGIKER, UPV/EHU). We are grateful to Paulo Fanado for editing this manuscript.
Funding Information:
A.M.V.Q thanks the financial support provided by CAPES/Brazil through postgraduate. MSS thanks to CNPq/Brazil for the Research Grant (Bolsa de Produtividade). DMAG thanks a traveling grant to visit JHU from Fundación Biofísica Bizkaia (Spain). C.S.P.R. thanks a summer fellowship from the Basque Country government “Becas Ikasiker de Colaboración 2019”. We thank Dr. Yana Li (JHU) for technical assistance. TEM images were collected at the Servicio General de Microscopía Analítica y de Alta Resolución en Biomedicina (SGIKER, UPV/EHU). We are grateful to Paulo Fanado for editing this manuscript.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/7/30
Y1 - 2021/7/30
N2 - Background: The infection caused by the protozoan Trypanosoma cruzi affects humans and is called as Chagas disease. Currently, the main measures available to reduce the incidence of this disease are drug treatment and vector control. Traditionally, the development of vaccines occurs mainly through the use of antigenic candidates of the etiologic agent in the form of a vaccine preparation. Virus-like particles (VLPs) are structures analogous to viral capsids composed essentially of structural proteins and are widely used in vaccination protocols because of their immunostimulatory properties. In this context, the objective of this study was to use strategies in a murine immunization model to characterize the immunostimulatory capacity of VLPs from Triatoma virus (TrV-VLPs), analysed in the presence or absence of the aluminium vaccine adjuvant. In parallel, to characterize the immunogenic behaviour of four T. cruzi chimeric recombinant proteins (mix-IBMP) associated with TrV-VLPs or aluminium vaccine adjuvant. Method: We immunized BALB/c mice once or twice, depending on the strategy, and collected serum samples at 15, 30 and 45 days after the immunization. Subsequently, serum samples from animals immunized with TrV-VLPs were used to determine total IgG, IgG1, IgG2a, IgG2b and IgG3 anti-TrV-VLPs by enzyme-linked immunosorbent assay (ELISA). Results: Data obtained demonstrate the ability of TrV-VLPs to preferably induce IgG2b and IgG3 type antibodies in the absence of aluminium adjuvant. In fact, the use of aluminium did not interfere with the total IgG profile of anti-TrV-VLPs. Interestingly, mix-IBMP had a better profile of total IgG, IgG1 and IgG3 subclasses when mixed with TrV-VLPs. Conclusion: In conclusion, these results suggest the potential of TrV-VLPs as a vaccine adjuvant and the use of T. cruzi chimeric antigens as a rational strategy for the development of vaccines against the experimental model of Chagas disease.
AB - Background: The infection caused by the protozoan Trypanosoma cruzi affects humans and is called as Chagas disease. Currently, the main measures available to reduce the incidence of this disease are drug treatment and vector control. Traditionally, the development of vaccines occurs mainly through the use of antigenic candidates of the etiologic agent in the form of a vaccine preparation. Virus-like particles (VLPs) are structures analogous to viral capsids composed essentially of structural proteins and are widely used in vaccination protocols because of their immunostimulatory properties. In this context, the objective of this study was to use strategies in a murine immunization model to characterize the immunostimulatory capacity of VLPs from Triatoma virus (TrV-VLPs), analysed in the presence or absence of the aluminium vaccine adjuvant. In parallel, to characterize the immunogenic behaviour of four T. cruzi chimeric recombinant proteins (mix-IBMP) associated with TrV-VLPs or aluminium vaccine adjuvant. Method: We immunized BALB/c mice once or twice, depending on the strategy, and collected serum samples at 15, 30 and 45 days after the immunization. Subsequently, serum samples from animals immunized with TrV-VLPs were used to determine total IgG, IgG1, IgG2a, IgG2b and IgG3 anti-TrV-VLPs by enzyme-linked immunosorbent assay (ELISA). Results: Data obtained demonstrate the ability of TrV-VLPs to preferably induce IgG2b and IgG3 type antibodies in the absence of aluminium adjuvant. In fact, the use of aluminium did not interfere with the total IgG profile of anti-TrV-VLPs. Interestingly, mix-IBMP had a better profile of total IgG, IgG1 and IgG3 subclasses when mixed with TrV-VLPs. Conclusion: In conclusion, these results suggest the potential of TrV-VLPs as a vaccine adjuvant and the use of T. cruzi chimeric antigens as a rational strategy for the development of vaccines against the experimental model of Chagas disease.
KW - Adjuvant
KW - Chagas disease
KW - Humoral immune response
KW - Triatoma virus
KW - Trypanosoma cruzi
KW - Virus-like particles (VLPs)
KW - virus-like particles
KW - VLPs
KW - VLP
UR - http://www.scopus.com/inward/record.url?scp=85107155224&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/34053789/
U2 - 10.1016/j.vaccine.2021.05.039
DO - 10.1016/j.vaccine.2021.05.039
M3 - Article
C2 - 34053789
AN - SCOPUS:85107155224
SN - 0264-410X
VL - 39
SP - 4723
EP - 4732
JO - Vaccine
JF - Vaccine
IS - 33
ER -